Sample & Assay Technologies QIAGEN 2012 Annual General Meeting June 26, 2013, Venlo, the Netherlands Peer M. Schatz, Chief Executive Officer
Forward looking statements Sample & Assay Technologies Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Regulation G: Some of the slides in this presentation contain certain summary information about QIAGEN N.V.’s sales, gross profit, operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases, which can be found in the Investor Relations section of QIAGEN’s webpage under www.QIAGEN.com, for information on the Company’s operating income, net income, and earnings per share presented on a GAAP basis. Such GAAP-basis information will also be contained in the Company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission. 2 QIAGEN Annual General Meeting - June 26, 2013
Agenda Sample & Assay Technologies Prof. Dr. Detlev H. Riesner Introduction Chairman of the Supervisory Board Peer Schatz QIAGEN strategy update CEO Annual General Meeting 3 QIAGEN Annual General Meeting - June 26, 2013
Our mission, vision and strategy Sample & Assay Technologies A world where our Sample & Assay Technologies Vision Future we envision “Make Improvements in Life Possible” Market and technology leadership in enabling access Mission Defines our purpose to content in biological samples How to achieve vision We leverage our Sample & Assay Technology Strategy and fulfill mission leadership across customer classes 4 QIAGEN Annual General Meeting - June 26, 2013
Making improvements in life possible Sample & Assay Technologies Molecular Diagnostics Applied Testing Pharma Academia How do we secure How do we achieve How do we fight diseases How do we develop food supplies and protect scientific breakthroughs and improve healthcare? better and safer drugs? public safety? even faster? Molecular revolution is only just beginning 5 QIAGEN Annual General Meeting - June 26, 2013
World leader in Sample & Assay Technologies Sample & Assay Technologies Enable access to molecular information > 500 core products > 500,000 customers worldwide Innovative power Healthy financial position 2012 key figures (In $ millions) 1 Net sales 1,254 + 10% (CER) Adjusted net income 260.7 11% Adjusted EPS (in $ per share) 1.08 Employees ~4,000 (1) US-GAAP results CER – Constant exchange rates 6 QIAGEN Annual General Meeting - June 26, 2013
Broad product offering with common purpose Sample & Assay Technologies From biological sample to highest-value interpretable result VALUABLE BIOLOGICAL SAMPLE Technologies ASSAY Technologies MOLECULAR SAMPLE INFORMATION Extract DNA, RNA and Make molecular info visible proteins in reliable process and available for interpretation 7 QIAGEN Annual General Meeting - June 26, 2013
Comprehensive product range to support workflows Sample & Assay Technologies Consumables Instruments 86% 14% 2012 net sales: $1.25 billion Leading portfolio of molecular tests for use with range of instruments 8 QIAGEN Annual General Meeting - June 26, 2013
Supporting >500,000 customers worldwide Sample & Assay Technologies 2012 sales Key customers Product highlights Reference labs Prevention: HPV, QuantiFERON-TB ~49% Hospitals Profiling: Infectious diseases Personalized Healthcare: Companion diagnostics Point of Need: AmniSure, ESE Molecular Diagnostics Forensic labs Human identification / forensics ~8% Industrial Veterinary medicine Governments Food safety Applied Testing Big Pharma Gene and pathway analysis ~19% Specialty / Biotech Biomarkers CROs Pharma Government research Life sciences research ~24% Academic labs Translational medicine Academia 9 QIAGEN Annual General Meeting - June 26, 2013
Sustained sales and earnings improvement Sample & Assay Technologies Adjusted net income 1 Net sales In $ m In $ m 1,400 1,255 1,170 1,200 1,087 1,010 1,000 893 300 261 234 250 800 223 200 200 600 163 150 400 100 200 50 0 0 2008 2009 2010 2011 2012 2008 2009 2010 2011 2012 2008 – 2012 CAGR = 14% 2008 – 2012 CAGR = 19% (1) US-GAAP results CAGR – Compound annual growth rate Net income adjusted excluding business integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) 10 QIAGEN Annual General Meeting - June 26, 2013
Full-year 2012: All customer classes deliver higher sales Sample & Assay Technologies 2012 net sales: $1.25 billion (+10% CER) MDx HPV Applied growth Pharma Academia (U.S.) Testing drivers (RoW) 2012 sales U.S.: ~12% ~33% ~8% ~19% ~24% contribution RoW: ~4% Change +33% -8% +22% +5% +1% (CER) Rapid growth from Molecular Diagnostics growth drivers and Applied Testing RoW – Rest of world CER – Constant exchange rates 11 QIAGEN Annual General Meeting - June 26, 2013
Full year 2012: US-GAAP and IFRS results Sample & Assay Technologies QIAGEN N.V. Consolidated Income Statement for year ended December 31, 2012 IFRS US-GAAP IFRS vs. In $ thousands (Except per share data) 2012 2012 US-GAAP Net sales 1,254,456 1,254,456 0 Income from operations 171,174 169,814 1,360 Net income 126,222 129,537 (3,315) Earnings per share attributable to equity holders of QIAGEN N.V. (Basic and diluted) Weighted average number of common shares, basic 235,582 235,582 0% Basic in $ per share 0.54 0.55 (0.01) Weighted average number of common shares, diluted 237,923 240,746 (2,823) Diluted in $ per share 0.53 0.54 (0.01) No material difference between US-GAAP and IFRS results 12 QIAGEN Annual General Meeting - June 26, 2013
Full year 2012: Key results (US-GAAP) Sample & Assay Technologies In $ millions Change FY 2012 FY 2011 $ (CER) (Except EPS) +7% +6% CER growth from recent acquisitions Net sales 1,254.5 1,169.7 (+10% CER) Adjusted gross profit 896.9 832.5 +8% Adjusted gross profit margin 71% 71% Adjusted operating income 356.4 319.6 +12% Achieved 2012 margin goal, strong finish Adjusted operating income margin 28% 27% In line with 2012 assumptions Adjusted tax rate 21% 24% Adjusted net income 260.7 234.4 +11% Exceeded $1.06 target Adjusted EPS 1.08 0.98 Weighted average number of diluted 240.7 239.1 common shares (In millions) CER – Constant exchange rates For further information on adjustments, please refer to the reconciliation tables in QIAGEN's Q4 2012 earnings release or appendices. Adjusted net income and adjusted EPS based on net income attributable to owners of QIAGEN N.V. 13 QIAGEN Annual General Meeting - June 26, 2013
Driving innovation and growth in 2012 Sample & Assay Technologies Initiatives 2012 achievements Exceeded QIAsymphony placement goal Drive platform NGS initiative success HPV automation U.S. approvals / EU clearance Rotor-Gene Q PCR cycler therascreen KRAS artus Influenza therascreen BRAF Add content Completed U.S. submissions therascreen EGFR QuantiFERON CMV New pharma co-development deals >35 projects in MDx pipeline AmniSure ROM test Broaden geographic Dynamic growth in top 7 EGM presence New structure and leadership changes Grow efficiently Free up resources to reinvest and effectively 14 QIAGEN Annual General Meeting - June 26, 2013
Recommend
More recommend
